Clinical Trial Update: Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating vorinostat for ductal carcinoma in situ of the breast has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ of the Breast

Drugs mentioned

• Zolinza (vorinostat)

Snippet

Sponsor: University of California, San Francisco | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED